Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging

Daniel G. Dyer
John A. Dunn
Suzanne R. Thorpe
Karen E. Bailie
Timothy L. Lyons

See next page for additional authors

Follow this and additional works at: https://scholarcommons.sc.edu/chem_facpub

Part of the Chemistry Commons

Publication Info
Published in Journal of Clinical Investigation, Volume 91, Issue 6, 1993, pages 2463-2469.
http://www.the-asci.org/aboutjci.shtml
© 1993 by the American Society for Clinical Investigation

This Article is brought to you by the Chemistry and Biochemistry, Department of at Scholar Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of Scholar Commons. For more information, please contact digres@mailbox.sc.edu.
Author(s)
Daniel G. Dyer, John A. Dunn, Suzanne R. Thorpe, Karen E. Bailie, Timothy L. Lyons, David R. McCance, and John W. Baynes

This article is available at Scholar Commons: https://scholarcommons.sc.edu/chem_facpub/5
Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging

Daniel G. Dyer,* John A. Dunn,* Suzanne R. Thorpe,* Karen E. Bailie,* Timothy J. Lyons,†† David R. McCance,‡ and John W. Baynes*†

*Department of Chemistry and Biochemistry, and †School of Medicine, University of South Carolina, Columbia, South Carolina 29208; †Department of Medicine, Altnagelvin Hospital, Londonderry BT47 1JE, Northern Ireland, United Kingdom; ‡Sir George E. Clark Metabolic Unit, Royal Victoria Hospital, Belfast BT12 6BA, Northern Ireland, United Kingdom; Division of Endocrinology, Diabetes and Metabolism, Medical University of South Carolina, Charleston, South Carolina 29425; and Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, South Carolina 29401

Abstract

To investigate the contribution of glycation and oxidation reactions to the modification of insoluble collagen in aging and diabetes, Maillard reaction products were measured in skin collagen from 39 type 1 diabetic patients and 52 nondiabetic control subjects. Compounds studied included fructoselysine (FL), the initial glycation product, and the glyoxidation products, \( N^\gamma-(\text{carboxymethyl})\)lysine (CML) and pentosidine, formed during later Maillard reactions. Collagen-linked fluorescence was also studied. In nondiabetic subjects, glycation of collagen (FL content) increased only 33% between 20 and 85 yr of age. In contrast, CML, pentosidine and fluorescence increased fivefold, correlating strongly with age. In diabetic patients, collagen FL was increased threefold compared with nondiabetic subjects, correlating strongly with glycated hemoglobin but not with age. Collagen CML, pentosidine and fluorescence were increased up to twofold in diabetic compared with control patients: this could be explained by the increase in glycation alone, without invoking increased oxidative stress. There were strong correlations among CML, pentosidine and fluorescence in both groups, providing evidence for age-dependent chemical modification of collagen via the Maillard reaction, and acceleration of this process in diabetes. These results support the description of diabetes as a disease characterized by accelerated chemical aging of long-lived tissue proteins. (J. Clin. Invest. 1993. 91:2463–2469.) Key words: aging • collagen • diabetes • glycation • oxidation

Introduction

Glycation (nonenzymatic glycosylation) is a nonenzymatic, posttranslational modification of protein, resulting from chemical reactions between glucose and primary amino groups (1). The major product in tissue proteins is fructoselysine (FL), formed by glycation of \( \gamma \)-amino groups on lysine residues (Fig. 1). The extent of glycation of tissue proteins depends on the ambient glucose concentration and is relatively constant with age (2–4). However, products formed from FL in subsequent Maillard or browning reactions accumulate gradually with advancing age in long-lived tissue proteins (2–4). These products include \( N^\gamma-(\text{carboxymethyl})\)lysine (CML) and \( N^\gamma-(\text{carboxymethyl})\)hydroxlysine (CMH), which are formed by oxidative cleavage of FL and glycated hydroxlysine respectively (3, 4), pentosidine, a fluorescent crosslink formed between arginine and lysine residues (5–7) (Fig. 1), as well as unidentified compounds with characteristic Maillard-type, visible wavelength fluorescence (maxima at Ex = 328 nm, Em = 378 nm) (4). CML, CMH, and pentosidine have been termed “glycoxidation” products (4, 8) because both glycation and free radical oxidation reactions are required for their formation from reducing sugars. The exact origin of these compounds, i.e., from glucose vs. ribose (5), ascorbate (6, 7, 9), or other sugars (8), is uncertain, although present evidence suggests that they are derived exclusively from reactions between proteins and carbohydrates (8).

According to the “glycation hypothesis” of aging and the pathogenesis of diabetic complications, accumulation of end-stage products of the Maillard reaction (also known as advanced glycosylation end-products [AGE products]) alters the structural properties of tissue proteins and reduces their susceptibility to catabolism (10, 11). These changes contribute to the aging of tissues, and when accelerated by hyperglycemia, to the gradual development of diabetic complications. Despite the attractiveness of this hypothesis, the only Maillard products known to accumulate with age, i.e., CML, CMH, and pentosidine, result not from glycation alone: oxidation reactions are also necessary for their formation (2–4, 7, 11). The development of increased fluorescence of proteins in diabetes and aging is also enhanced by oxidation reactions, and carbohydrate- or lipid-dependent processes may also be involved (8). These considerations raise questions about the relative importance of the glycation and oxidation components of glycoxidation in the accumulation of Maillard products in tissue proteins.

To our knowledge, no previous studies have made direct comparisons between the concentrations and relative rates of accumulation of the glycoxidation products CML and pentosidine in collagen from control and diabetic populations. There is a similar lack of information on the relative contributions of

1. Abbreviations used in this paper: CMH, \( N^\gamma-(\text{carboxymethyl})\)hydroxlysine; CML, \( N^\gamma-(\text{carboxymethyl})\)lysine; FL, fructoselysine; Hb, hemoglobin.
increased glycation vs. increased oxidation in the accumulation of these products. We have attempted to address these issues in the present study, and show that concentrations of CML and pentosidine, and Maillard-type fluorescence, increase in concert in human skin collagen with age, and that the rate of their increase is accelerated, again in a concerted fashion, in diabetes. Our data also suggest that the accelerated accumulation of glyoxidation products in diabetes can be explained by hyperglycemia and increased glycation alone, without invoking an increase in oxidative stress.

Our findings support the description of diabetes as a disease characterized by accelerated chemical modification and aging of collagen via the Maillard reaction. The relationships between concentrations of these biomarkers and the presence and severity of complications in diabetes are considered in the following article (12).

Methods

Diabetic patients and control subjects. A total of 91 people were enrolled in this study: 39 patients (27 male, 12 female) with insulin-dependent (type 1) diabetes mellitus, aged 17–73 yr (41.1±15.3 yr, mean±SD), duration of diabetes 0–46 yr (17.2±11.5 yr), and 52 nondiabetic control subjects, aged 0–85 yr (47.6±25.9 yr). The nondiabetic control skin samples were obtained from healthy, nondiabetic donors, or at autopsy at the Royal Victoria Hospital in Belfast, Northern Ireland. Autopsy samples were taken within 6 h of death from patients who had died of acute illness, e.g., stillbirth, severe congenital heart disease, trauma, or myocardial infarction. These patients had no history of diabetes and, where possible, had documented normal plasma glucose levels during their terminal illnesses. Some analytical data on the control patients (skin collagen FL and CML concentrations) have been reported previously (3). Live participants in each group were healthy and free of ailments known to elicit inflammatory responses, such as infection, the inflammatory arthropathies, or rheumatoid arthritis. Clinical characterization of the diabetic and the nondiabetic subjects is presented in the following article (12).

Skin samples. An elliptical full-thickness skin biopsy (≈ 0.5 × 1.0 cm) was taken from the medial aspect of the buttock (under 2% lidocaine local anesthesia in live donors). For ~ 15% of the samples, insufficient collagen was available to perform all assays. Thus, the number of samples in some analyses may not always be equal to the number of people involved in the study. Informed consent was obtained from all participants, and the study was approved by the Ethical and Human Subjects Committees of the participating institutions.

Materials. Unless otherwise indicated, reagents were of the highest quality obtainable from Sigma Chemical Co. (St. Louis, MO). The preparation of FL, CML, and pentosidine standards have been described previously (3, 7).

Analytical procedures. Procedures for sample storage, for isolation of insoluble collagen by extraction with 1 M NaCl, 0.5 M acetic acid, and organic solvents, and for acid hydrolysis of the collagen have been described previously (3). FL, CML, and lysine in collagen hydrolysates were measured as their N-trifluoracetyl methyl esters by selected ion monitoring gas chromatography—mass spectrometry, as described previously (3). Amounts of FL and CML were normalized to the lysine content of the collagen by external standardization (13) using calibration curves generated from solutions with constant lysine content and variable concentrations of the other analytes. Samples were analyzed in random order without knowledge of the sample identity. Pentosidine was measured in collagen hydrolysates by reversed-phase HPLC using postcolumn fluorescence detection (Ex = 328 nm, Em = 378 nm), as described previously (7). The assay was standardized with a preparation of pentosidine labeled with [4,5-3H]lysine of known specific radioactivity (7). Collagen-linked fluorescence was measured in collagen solubilized by digestion with 2% pepsin in 0.5 M acetic acid for 24 h at 37°C. Fluorescence was measured at both Ex = 328 nm, Em = 378 nm and Ex = 370 nm, Em = 440 nm, and normalized to the hydroxyproline content of collagen, measured according to Stegemann and Stalder (14), as modified by Mackawa et al. (15). Hemoglobin (Hb) A1 was measured by agar gel electrophoresis (Corning Medical, Halsted, England) after saline incubation to remove labile hemoglobin (16). In the 39 diabetic patients, HbA1c (mean±SD) was 11.4±2.4%, range 6.9–16.9%. In 24 of these patients, HbA1c values had been obtained every 3 mo for 6 yr preceding the skin biopsy, as described (12). From these results, a mean HbA1c (MHBa1c) was determined for each patient, and this correlated with recent HbA1c (r = 0.78, P < 0.0001). The normal laboratory range for HbA1c in nondiabetic subjects (mean±2 SD) is 3.6–7.2%.

Statistical analysis. Data are shown as means±1 SD. Correlation analyses were performed using the linear least squares method. Statistical data are summarized in figure legends.

Results

Glycation of collagen. In a previous study of the nondiabetic subjects (3), a slight, but statistically significant, increase in the extent of glycation (FL content) of skin collagen with age was observed. As shown by the lower line in Fig. 2 (from reference 3, Fig. 4), this amounted to a 33% increase in glycation of lysine residues in skin collagen between the ages of 20 and 85 yr.
(r = 0.55, P < 0.001). The upper line in Fig. 2 illustrates that glycation of collagen from the diabetic patients was increased approximately threefold compared with collagen from the non-diabetic control subjects. In the diabetic group, collagen glycation did not correlate either with age or duration of diabetes (P > 0.05). There was a significant correlation between collagen glycation and HbA1c in these patients (r = 0.74, P < 0.0001, n = 37), confirming the results of previous studies (17, 18); this correlation was strengthened when MHBa1c was used in the analysis (r = 0.89, P < 0.0001, n = 23) (Fig. 3).

\[ \text{mmol FL/mol Lys} = [0.029 \times \text{age (yr)}] + 3.27, (r = 0.54, P < 0.001). \]

There was no significant relationship between age and skin collagen glycation in the diabetic patients.

\[ \text{mmol CML/mol Lys} = [0.027 \times \text{age}] - 0.015 (r = 0.84, P < 0.001). \]

**Glycoxidation products and fluorescence.** In previous studies, we have shown that, in contrast to FL, there is a substantial age-dependent increase in the concentration of CML in skin collagen from control subjects (3), i.e., about a fivefold increase between the ages of 20 and 80 yr. As shown in Fig. 4, the concentration of CML also increases with age in collagen from diabetic subjects, but levels of CML in collagen from diabetic subjects are significantly greater than those found in nondiabetic subjects. Analyses for pentosidine (Fig. 5) and fluorescence (Fig. 6) also showed substantial age-dependent increases, with higher levels in collagen from diabetic, compared with age-matched nondiabetic, subjects. To determine the significance of the differences between the two groups, each measurement was expressed as a ratio of the observed value to the

\[ \text{CML} = 0.41 \times \text{age} + 0.48 (r = 0.38, P < 0.001). \]
predicted value for a control subject of the same age, obtained from the regression line for the control population (Figs. 4–6).

By these analyses (Fig. 7), the control and diabetic populations differed significantly in age-corrected levels of FL, CML, pentosidine, and fluorescence in skin collagen (P < 0.001). In contrast to FL, concentrations of CML and pentosidine, and also fluorescence, correlated significantly with duration of diabetes (CML r = 0.74; pentosidine r = 0.77; fluorescence r = 0.71, P < 0.001); these correlations persisted to varying degrees when the concentrations were standardized for age (CML \( r = 0.34, P < 0.05 \); pentosidine \( r = 0.75, P < 0.001 \); fluorescence \( r = 0.58, P < 0.01 \)).

The strong correlations among the various Maillard products in the control and diabetic populations are summarized in Fig. 8. The correlations between fluorescence and pentosidine in both groups (Fig. 8, top panel) are consistent with the observation that pentosidine accounts for ~ 30% of the fluorescence in collagen at Ex = 328 nm, Em = 378 nm (4, 7). There were equally strong correlations between levels of the two glyoxidation products, CML and pentosidine, in collagen from both the control and diabetic groups (Fig. 8, bottom panel). Similarly, the correlations between CML and fluorescence (graph not shown) were highly significant for both groups (control \( r = 0.94, P < 0.001 \); diabetic \( r = 0.95, P < 0.001 \)).

Choice of fluorescence maxima. In many reports on “Maillard-type” fluorescence in proteins, measurements are conducted at excitation and emission wavelengths of 370 and 440 nm, respectively. The recent work identifying pentosidine as a major Maillard reaction fluorophore (5, 7) and three-dimensional fluorescence spectra of proteins browned by glucose (4, 8) both suggest that the fluorescence characteristic of the Maillard reaction has excitation and emission maxima close to the maxima for pentosidine, i.e., 328 and 378 nm, respectively. As illustrated in Fig. 9, there is a strong correlation between fluorescence of collagen at Ex/Em = 370/440 and that at Ex/Em = 328/378 nm. However, the fluorescence intensity is about twice as great at Ex/Em = 328/378 nm as at Ex/Em = 370/440 nm, providing a twofold increase in sensitivity for measurement of Maillard-type fluorescence in collagen if these wavelengths are used.

**Figure 7.** Comparison of age-normalized levels of FL, CML, pentosidine, and fluorescence in skin collagen from control subjects (C) and diabetic patients (D). The observed value of each parameter for each donor was divided by the calculated value, based on the regression equation for the control population (shown in the legends to Figs. 4–6), then expressed as the ratio of observed to calculated value. Means ± 1 SD of the ratios are shown.

**Figure 6.** Effects of age and diabetes on Maillard-type fluorescence (Ex = 328 nm, Em = 378 nm) in human skin collagen. The equation of the line for the control subjects is: fluorescence units/μg Hyp = [0.032 × age] + 0.056 (r = 0.92, P < 0.001); and for the diabetic patients: fluorescence units/μg Hyp = [0.047 × age] − 0.047 (r = 0.86, P < 0.001).
that CML and significant controls. The diabetic glycemia, our data demonstrate that, again in contrast to glycoxidation products or fluorescence, Amadori adducts increase only slightly with age in both control and diabetic populations.

Changes in glycation (Maillard) products and fluorescence. Comparative analyses of CML, pentosidine, and Maillard-type fluorescence in skin collagen (Figs. 4–6) indicate that both glycation and fluorescence are increased in collagen from diabetic patients, compared with age-matched nondiabetic controls. The age-normalized data in Fig. 7 also indicate significant differences between the diabetic and control populations in all parameters, independent of age. These results suggest that the increased accumulation of pentosidine (as well as CML and fluorescence) is not confined to a subset of diabetic patients with renal complications, as has been suggested (11), but rather that it is a general feature of the disease process. The comparisons in Fig. 8 emphasize the strong correlations among these three parameters of chemical damage to collagen. The fact that CML and pentosidine are so dissimilar in their structure and physical properties, yet increase in concert both with age and in diabetes, emphasizes their common origin from glycation reactions. Because the age-dependent rate of chemical modification of skin collagen, as measured by the accumulation of glycoxidation products, is accelerated in the diabetic patients, diabetes may be properly described as a disease characterized, at the chemical level, by accelerated aging of collagen. Although CML and pentosidine are only two out of many, as yet unidentified, products of the Maillard reaction, they may be regarded as “biomarkers” of the overall extent of glycoxidative aging of proteins (8) in both nondiabetic and diabetic populations.

Role of oxidative stress. In recent work from several laboratories (8, 20–24), oxidative stress and increased oxidative damage to biomolecules have been proposed as possible unifying mechanisms for the development of complications in diabetes. Although the level of glycoxidative damage to collagen is clearly increased in the diabetic patients (Fig. 7), an important question that can be asked from our data is whether the increased levels of glycoxidation products in collagen can be attributed solely to the increase in glycation, or whether an increase in oxidative stress is also involved. For this reason we have attempted to predict the levels of glycoxidation products and fluorescence in our diabetic patients, based on the age of onset and duration of diabetes, and the relative increase in glycemia. The assumption is made that Maillard products accumulated in collagen at a “normal” rate until the onset of diabetes, and thereafter at an accelerated rate, the difference being directly proportional to the increase in glycation of protein, either collagen or hemoglobin. The age of onset and duration of diabetes were known for each patient, and we used each patient’s relative increase in glycation of either collagen or hemoglobin, compared to age-matched controls, at the time of biopsy as an indicator of long-term glycemic control. The following formula was used for the calculations:

\[ PL = CR[AO + (RG \times D)], \]

where \( PL \) = predicted level of glycoxidation product or fluorescence; \( CR \) = control rate of accumulation (per year) of glycoxidation product or fluorescence in collagen, i.e., slope of control (lower) line in Figs. 4–6; \( AO \) = age of onset of diabetes (years); \( RG \) = ratio of glycation of collagen or hemoglobin (%HbA,) in
the patient, compared with age-matched nondiabetic control subject; \( D \) = duration of diabetes (years).

From these calculations, ratios of observed (actual) to predicted values for each parameter were calculated. As shown in Table I, the observed levels of each glycoxidation product and fluorescence in diabetic skin collagen were consistently lower than predicted. The underestimate was more marked when based on the relative increase in glycation of collagen than hemoglobin in diabetic patients. Also, the underestimate remained if mean HbA1c values (calculated from results obtained every 3 mo over a 6-yr period preceding the skin biopsy) were used in the calculation. Thus, in all cases, observed levels were lower than would be expected. We conclude that the increased accumulation of glycoxidation products and fluorescence in diabetic skin collagen can be explained, on average, solely by the increase in glycation for the duration of disease: we have found no evidence of a general increase in oxidative stress in diabetes. Indeed, the lower than expected levels of glycoxidation products and fluorescence, i.e., the ratios of < 1.0 in Table I, suggest that oxidative stress may actually be decreased, on average, in diabetic patients. These analyses assume that CML, pentosidine, and fluorescence are derived predominantly from interactions between proteins and glucose (i.e., as opposed to ribose or ascorbate), and that the increase in glycoxidation products is related to the increase in average glycemia, as measured by the increase in glycation of proteins. The conclusions are valid unless one assumes that the rate of formation of CML, pentosidine, and increased fluorescence in collagen is primarily determined by factors other than the extent of glycation of proteins, e.g., variations in oxidative stress and/or levels of carbohydrates other than glucose. Although this hypothesis cannot be excluded, and although a possible role for increased oxidative stress has recently been emphasized by Wolff et al. (23), we have found a strong correlation between levels of FL and CML in urine from diabetic patients, suggesting a relationship between glycation of protein and the formation of CML (25). Notably, in that study, we observed that the ratio of CML to FL was decreased in urine from diabetic, compared with nondiabetic, subjects. Again, this is consistent with a decrease in oxidative stress in diabetic subjects. In relation to the possibility that CML is derived to a significant extent from sources other than glycated proteins, recent (unpublished) findings in our laboratory have shown that plasma pentose levels are not increased in type 1 diabetic patients, and that in nondiabetic guinea pigs, ascorbate supplementation does not result in increased collagen FL, CML, or pentosidine content.

Regardless of the status of oxidative stress in diabetes, it is clear that the net glycoxidative modification of collagen is increased. It is also evident from the large standard deviations shown in Table I that the ratios, based on either glycation of collagen or hemoglobin, are not normally distributed about the mean. This implies that, although the average ratio of observed to predicted values is < 1.0, some patients have levels of glycoxidation products and fluorescence which are much higher than would be predicted from duration of diabetes and severity of hyperglycemia. The presence of higher than average oxidative stress in these patients may be an inherent characteristic, unrelated to the presence of diabetes. Indeed, a considerable variation in the rates of accumulation of glycoxidation products with age, despite similar glycaemia, is seen in the nondiabetic population (Figs. 4–6). Diabetic individuals who are also under high oxidative stress and are therefore rapid accumulators of glycoxidation products may be particularly vulnerable to the development of complications. The association between levels of skin collagen glycoxidation products and complication status is discussed further in the following article.

**Acknowledgments**

The authors wish to thank Professor D. R. Hadden, Dr. L. Kennedy, and Dr. A. B. Atkinson (Royal Victoria Hospital), and Drs. D. A. J. Keegan, F. A. O’Connor, and W. E. Parkes (Altnagelvin Hospital) for permission to study patients under their care. We are grateful to the staff of the Biochemistry and Hematology Departments at the Royal Victoria and Altnagelvin Hospitals, to Drs. D. J. Pettitt and R. L. Hanson for statistical advice, and to Drs. D. J. Pettitt and P. H. Bennett for helpful discussions.

This work was supported in part by research grant DK-19971 from the National Institute of Diabetes, Digestive and Kidney Diseases (USA).

**References**


---

**Table I. Ratio of Observed to Predicted Concentrations of Glycoxidation Products and Fluorescence in Skin Collagen from Diabetic Patients**

<table>
<thead>
<tr>
<th>Measurement</th>
<th>Glycation of collagen ratio*</th>
<th>Glycation of hemoglobin ratio*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CML</td>
<td>0.74±0.32</td>
<td>0.82±0.37</td>
</tr>
<tr>
<td>Pentosidine</td>
<td>0.65±0.41</td>
<td>0.79±0.50</td>
</tr>
<tr>
<td>Fluorescence</td>
<td>0.60±0.33</td>
<td>0.73±0.38</td>
</tr>
</tbody>
</table>

* Ratios of observed to predicted concentrations of glycoxidation products and fluorescence. The predicted values are calculated as described by Eq. 1 (see Discussion), using the relative increase in glycation of collagen (FL) (left column) or hemoglobin (HbA1c) (right column) for individual patients (mean±SD).


